Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2010

View Archived Issues

Pritumumab is active in patients with brain cancer

GlycoVaxyn reports phase I data on Shigella dysenteriae vaccine

IPI-926 is well tolerated and active in patients with solid tumors

GAA peptide-loaded DC1-based vaccine shows promise in recurrent malignant glioma

French scientists claim new inhibitors of cell division protein kinases

Prosidion describes new GPR119 receptor agonists

Continuous exenatide delivery with ITCA-650 shows promise in phase II diabetes trial

Preclinical and phase I data presented on Algipharma's OligoG

Takeda and Envoy Therapeutics collaborate on schizophrenia research

UCB and Synosia Therapeutics enter into strategic neurology alliance

Novartis renews agreement with WHO to provide free leprosy drugs

Bazedoxifene launched in Japan and Spain for postmenopausal osteoporosis

Almirall presents pharmacological profile of LAS-189913, a new candidate therapeutic for MS

Bristol-Myers Squibb acquires ZymoGenetics

First patient with spinal cord injury is treated in phase I trial of GRNOPC1

FDA funds phase I trial of genetically reprogrammed HSV in childhood cancer

Phase II trial studies sildenafil for heart failure in Duchenne's muscular dystrophy

Pfizer to acquire King Pharmaceuticals and expand pain product portfolio

FDA warns of increased risk of thigh bone fracture with bisphosphonates use

Merck & Co. claims new diacylglycerol O-acyltransferase 1 inhibitors

Olatec Industries patents agents with anti-inflammatory and analgesic potential

New deuterated alpha-(N-sulfonamido)acetamide beta-APP42 production inhibitors claimed

ERYtech and Genzyme to conduct feasibility studies with new therapeutic enzyme formulation

Shire acquires 99.21% of Movetis shares, proceeding with squeeze-out of remaining shares

Twice-daily tramadol/acetaminophen approved in eight European countries

Innate Therapeutics begins phase II trial of MIS-416 in progressive MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...